Effects of epidermal growth factor receptor antibody on cholangitis

LIU San-hu,JIANG Li-sheng,LI Fu-yu,YOU Xiao-xiang,HU Kai

2013-01-01

Abstract:【Objective】 To investigate the inhibitory action of epidermal growth factor receptor monoclonal antibody cetuximab on cell proliferation in chronic proliferative cholangitis(CPC).【Methods】 46 SD rats were assigned to 3 groups randomly.They were CPC group(n =10),cetuximab therapeutic group(n =30) and shame operation group(n =6) respectively.Rat model in CPC and cetuximab group was established by introducing a nylon stylolite into common bile duct.In cetuximab therapeutic group,cetuximab was administered into the common bile duct with concentration of 0.05%,0.1% and 0.2% respectively.As regards to shame operation group,surgical incision and suture of the abdomen were made as controls.Bile duct was removed 7 days after the initial operation.The anti-proliferation effect,dose-response relationship,and potential mechanism of cetuximab in chronic proliferative cholangitis was assessed through HE,PAS,Masson,immunohisto chemistry and RT-PCR of EGFR.【Results】 The degree of proliferation in cetuximab therapeutic group was less than that of CPC model group.No difference was found between 0.1% cetuximab subgroup(C 0.1%) and 0.2% Cetuximab subgroup(C 0.2%),however,the degree of proliferation of those two groups was less than that of 0.05% cetuximab subgroup(C 0.05%).The levels of EGFR and the expression of EGFR mRNA in C 0.2% and C 0.1% subgroup were less than that of CPC model group and no differences of the expression of EGFR and EGFR mRNA were found between C 0.1% and C 0.2% subgroup,nevertheless those expressions of above two subgroups were lower than that of C 0.05% subgroup.【Conclusions】 Cetuximab can effectively suppress proliferation in chronic proliferative cholangitis(CPC),and it may provide practical value in the treatment of intrahepatic chalangiocarcinoma.